Dan Lu

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Topics

Convolutional Neural Network

Health Insurance

Top Venues

CPT: pharmacometrics & systems pharmacology

PLoS computational biology

Cancer chemotherapy and pharmacology

Pharmaceutical research

This page only lists publications with an associated author ORCID identifier.

Publications

Gengbo Liu, Logan Brooks, John T Canty, Dan Lu, Jin Yan Jin, James Lu
Deep-NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Gengbo Liu, Logan Brooks, John T Canty, Dan Lu, Jin Yan Jin, James Lu
Deep-NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Gengbo Liu, Logan Brooks, John T Canty, Dan Lu, Jin Yan Jin, James Lu
Deep-NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Gengbo Liu, Logan Brooks, John T Canty, Dan Lu, Jin Yan Jin, James Lu
Deep-NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data. CPT: pharmacometrics & systems pharmacology (2024)
Gengbo Liu, Logan Brooks, John T Canty, Dan Lu, Jin Yan Jin, James Lu
Deep-NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Gengbo Liu, James Lu, Hong Seo Lim, Jin Yan Jin, Dan Lu
Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs. CPT: pharmacometrics & systems pharmacology (2022)
Victor Poon, Dan Lu
Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure-response relationships for large-molecule oncology drugs. CPT: pharmacometrics & systems pharmacology 11 (11) (2022)
Rong Shi, Tong Lu, Grace Ku, Hao Ding, Tomohisa Saito, Leonid Gibiansky, Priya Agarwal, Xiaobin Li, Jin Yan Jin, Sandhya Girish, Dale Miles, Chunze Li, Dan Lu
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer chemotherapy and pharmacology 86 (3) (2020)
Jennifer L Wilson, Dan Lu, Nick Corr, Aaron Fullerton, James Lu
An in vitro quantitative systems pharmacology approach for deconvolving mechanisms of drug-induced, multilineage cytopenias. PLoS computational biology 16 (7) (2020)
Dan Lu, Tong Lu, Rong Shi, Leonid Gibiansky, Priya Agarwal, Colby S Shemesh, Randall C Dere, Uzor Ogbu, Jamie Hirata, Pascal Chanu, Sandhya Girish, Jin Yan Jin, Chunze Li, Dale Miles
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. Pharmaceutical research 37 (12) (2020)
Dan Lu, Tong Lu, Leonid Gibiansky, Xiaobin Li, Chunze Li, Priya Agarwal, Colby S Shemesh, Rong Shi, Randall C Dere, Jamie Hirata, Dale Miles, Pascal Chanu, Sandhya Girish, Jin Yan Jin
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma. CPT: pharmacometrics & systems pharmacology 9 (1) (2019)